

John S. Abrams, PhD. has over 40 years of experience in the Biotechnology Industry, including several decades of senior executive science leadership (with over 20 years at DNAX Research Institute / Schering-Plough). He holds a BA degree in Biochemistry from UC Berkeley, and a PhD in Biochemistry from McGill University. He has authored over 100 scientific publications and holds over a dozen issued patents. Dr. Abrams has deep experience with early research program design, implementation, and team creation. He has been an independent consultant in the field of early stage biotechnology project implementation for over 15 years.

Dr Abrams believes that regulations and compliance in the nascent Medical Cannabis industry should be established in a scientifically sound and evidence-based manner. He brings his long standing interest in multivariate statistics and Design of Experiments (DOE) to the area of cannabis strain chemotype profiling. This work is aimed at devising a better way to classify Cannabis (moving away from species and strain towards actual product content). He is also applying antibody development and immunoassay-based technologies to develop unique solutions in the area of Cannabis product assays. Additionally, Dr. Abrams is collaborating on the launch of The Dosing Project, a self-reporting, crowd-sourced, indication-based, survey of cannabis use and efficacy. The Dosing Project is the lynchpin clinical-correlates program within the newly created Clinical Endocannabinoid System Consortium (CESC) Inc.; Dr. Abrams serves as its Chairman and Chief Scientific Officer. John is currently working on launching a new Cannabis Biotech start-up.